Because monotherapies have limited and/or opposing effects in allergic diseases, the focus has switched to the combined use of H4R and H1R antagonists as palliatives for allergic dermatitis and ACD, and progress has been made recently. This evidence concerns the gene HRH1 and atopic eczema.